In a phase I trial of the multi-kinase inhibitor sorafenib in combination with the farnesyltransferase inhibitor tipifarnib 5/13 patients with MTC showed a response, however the mutation status of the patients for RET and RAS was not reported (53). Here, RET is linked to medullary thyroid gland carcinoma.